Pretreatment Plasma Folate Modulates the Pharmacodynamic Effect of High-Dose Methotrexate in Children with Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma: “Folate Overrescue” Concept Revisited
Open Access
- 1 April 2006
- journal article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 52 (4), 692-700
- https://doi.org/10.1373/clinchem.2005.061150
Abstract
Background: To evaluate the influence of pretreatment plasma folate concentrations on methotrexate exposure in children with acute lymphoblastic leukemia/non-Hodgkin lymphoma treated with high-dose methotrexate, we assessed time profiles of plasma homocysteine, folate, and vitamin B12 concentrations in children treated with high-dose methotrexate with leucovorin rescue. Methods: We analyzed 98 treatment courses. The study endpoints were to determine how methotrexate exposure is related to homocysteine accumulation and whether it is influenced by pretreatment plasma folate. Results: Peak concentrations of homocysteine increased from the start of the intravenous infusion through cessation of methotrexate therapy up to time point t42, when this trend was reversed by administration of folinic acid. The area under the curve (AUC) for plasma homocysteine showed decreasing course-to-course tendencies with a statistically significant decrease only between courses 1 and 2 (P ≤0.05), indicating decreased whole-body homocysteine accumulation in response to administration of consecutive methotrexate courses. Therapeutic courses with low initial folate concentrations (≤10 nmol/L) gave significantly higher responses in homocysteine accumulation expressed both as hcysAUC0–66 h and the peak t42 homocysteine concentrations than did courses with initial folate >10 nmol/L. Correspondingly, in the courses with low initial folate, peak plasma concentrations of methotrexate were significantly higher than in courses with high precourse concentrations of plasma folate. Conclusion: Endogenous pretreatment plasma folate modulates the magnitude of the methotrexate effect, providing support for a “folate overrescue” concept.Keywords
This publication has 26 references indexed in Scilit:
- Severe Encephalopathy Induced by the First but Not the Second Course of High-Dose Methotrexate Mirrored by Plasma Homocysteine Elevations and Preceded by Extreme Differences in Pretreatment Plasma FolateOncology, 2005
- High folic acid levels and failure of single‐dose methotrexate treatment in ectopic pregnancyInternational Journal of Gynecology & Obstetrics, 2005
- The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95Blood, 2004
- High-Dose Methotrexate and Asparaginase for the Treatment of Children With Acute Lymphoblastic Leukemia: Why and How?Journal of Pediatric Hematology/Oncology, 2004
- Microarray reality checks in the context of a complex diseaseNature Biotechnology, 2004
- Acute Lymphoblastic Leukemia- Relapse Study of the Berlin-Frankfurt-Münster Group (ALL-REZ BFM) Experience: Early Treatment Intensity Makes the DifferenceJournal of Clinical Oncology, 2004
- Resistance to antifolatesOncogene, 2003
- How much is too much? Folinic acid rescue dose in children with acute lymphoblastic leukaemiaEuropean Journal of Cancer and Clinical Oncology, 1991
- Calculating Confidence Intervals for the Mean of a Lognormally Distributed VariableSoil Science Society of America Journal, 1990
- Rescue after Intermediate and High-Dose Methotrexate: Background, Rationale, and Current PracticePediatric Hematology and Oncology, 1990